Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.
Fleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. HIV-negative men were treated with a single 400-mg dose of fleroxacin, and HIV-positive men were treated with 400 mg daily for 5 days. Three of the 58 evaluable HIV-negative men were clinical and microbiologic failures, and two of the 22 evaluable HIV-positive men had persisting infection with Haemophilus ducreyi. Both regimens were well tolerated. Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men.
Tyndall
M W
MW
WHO Collaborating Centre for Research and Training in Sexually Transmitted Diseases, University of Nairobi, Kenya.
Plourde
P J
PJ
Agoki
E
E
Malisa
W
W
Ndinya-Achola
J O
JO
Plummer
F A
FA
Ronald
A R
AR
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D002602:Chancroid / Q000150:complications / Q000188:drug therapy*; D016576:Fleroxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D006679:HIV Seropositivity / Q000150:complications*; D015497:HIV-1 / Q000276:immunology*; D006191:Haemophilus ducreyi / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D016576:Fleroxacin